Incidental finding of drug-induced movement disorder
Objective: Recognizing a drug-induced movement disorder is critical as only stopping using over the counter dopamine-blocking medications such as metoclopramide can reverse or improve clinical…Three distinct cases of methamphetamine induced movement disorders
Objective: To detail three cases of methamphetamine induced movement disorders with unique clinical phenotypes. Background: MA is an addictive psychostimulant that affects both the central…Valproate-associated parkinsonism – A critical review of the literature
Objective: To provide a critical review of the existing literature on valproate-associated parkinsonism and to discuss possible mechanisms. Background: Valproate was first approved as an…MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum
Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…Persistent drug-induced parkinsonism with normal dopamine transporter imaging
Objective: We investigated whether patients with persistent drug-induced parkinsonism (DIP) showing visually normal dopamine transporter (DAT) imaging had minimal changes in striatal DAT activity using…A survey of movement disorders in a large sample of patients treated with antipsychotic medication
Objective: To describe the prevalence and nature of movement disorders (MD) in a large sample of patients treated with antipsychotic medication. Background: Although there are…The differentiated treatment of Parkinson’s disease in patients with concomitant diabetes mellitus(DM) type 2
Objective: To study the state of lipid metabolism in PD patients with concomitant type 2 diabetes with different glucose tolerance and the influence of the…Neuronal nicotinamide-N-methyltransferase (NNMT) in Parkinson’s disease
Objective: Understanding the role of NNMT in initiation and progression of Parkinson's disease (PD). Background: 10-15% of all PD cases are caused by genetic factors,…Risk of movement disorders with antipsychotic drugs in patients with schizophrenia or depressive disorders
Objective: To compare the risk of movement disorders with antipsychotic drugs (APDs) in patients suffering from Schizophrenia or Depressive Disorders. Background: APDs are well-known causes…Frequency of echogenic abnormality of the substantia nigra is increased in methamphetamine users
Objective: To investigate structural abnormality of the substantia nigra (SN) in methamphetamine users using transcranial sonography (TCS). Background: Epidemiologic studies suggest that chronic use of…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »